Veteran-Founded Temple Massager Shows How Mission-Driven Small Brands Can Build Clinical Evidence

With MOQ Collective and the People Science® platform (Chloe®), Army veteran Joe Meisch moved from years of field letters to a registered study

CAZADERO, Calif., Nov. 11, 2026 — This Veterans Day, Army veteran and inventor Joe Meisch, MOQ Collective and People Science are sharing how a small, service-disabled veteran-owned business built rigorous clinical evidence, and why that path should be open to more mission-driven brands.

For more than 15 years, Meisch has donated over 6,000 of his hand-held, drug-free Temple Massagers to service members, veterans and first responders, with signed letters from commanders, clinicians and police departments describing what they saw. What he lacked was the clinical data that health systems, employers and buyers increasingly expect.

"I know what it feels like when the stress and tension build up and you just need some relief," said Joe Meisch, inventor and CEO of Meisch Temple Massager, Inc. "Now we have research behind what I've been hearing from people for years, and I want to use that momentum to get this into the hands of people doing some of the most stressful jobs out there."

A fully remote, registered study

MOQ Collective ran the four-week, IRB-approved observational study (ClinicalTrials.gov NCT07639658) remotely on the People Science® platform (Chloe®). Women aged 35 to 65 with recurring headaches, facial tension or jaw clenching were recruited from the People Science community of more than 65,000 participants, and enrollment filled in under 12 hours. Participants used the device at home daily and reported through the Chloe app, with no site visits.

Among the 35 women in the main analysis (68 enrolled):

• 30 improved on a validated anxiety measure (GAD-7), with average scores falling from 9.91 to 5.11, a change generally considered clinically meaningful
• Improvement in 7 of 8 quality-of-life domains, including fatigue, sleep and pain interference
• Fewer headache days, and days using over-the-counter pain medication down from 1.66 to 0.71 per week
• No adverse events across 286 check-ins

The anxiety result held across all three pre-specified analyses and was independently reproduced from the raw data. Without a control group, the study shows what changed during use, not that the device alone caused it.

"Women's health has waited too long for evidence, and small, mission-driven brands are too often priced out of producing it," said Colleen Quinn, principal investigator, MOQ Collective. "Temple Massager's study shows that does not have to be the case. With a well-designed, fully remote study, a veteran-founded company with a simple, drug-free product generated registered, pre-specified clinical data, and the women who took part told us clearly how much they want options like this."

"We built Chloe so research partners like MOQ can bring rigorous, decentralized research to brands of every size, including those a traditional trial would price out," said Paige Oliver, head of product, People Science.

What's next

Meisch will bring these results to employers, health systems and government buyers, pursue controlled research, and keep working toward his goal of a Temple Massager in every U.S. 911 dispatch center.

Media contacts:
Temple Massager: Meredith Krantz, Krantz Strategies, [email protected], (630) 947-2385
MOQ Collective: Megan Morris, Managing Director, [email protected], (415) 320-0000
People Science: Laetitia d'Ursel, Head of Marketing, [email protected] 

SOURCE People Science, Inc.